MEDFORD, N.Y., June 18, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC") diagnostic tests for infectious diseases, announced today that it's SURE CHECK® HIV 1/2 Assay has received CE Mark approval from European regulators. The SURE CHECK® HIV 1/2 Assay is now cleared for commercialization within the European Union (EU) for rapid, point-of-care detection of HIV. This product is FDA-approved and distributed in the U.S. as Clearview® COMPLETE HIV 1/2 by Alere NA. Chembio is currently working with commercialization partners in Europe and expects sales of the SURE CHECK® HIV 1/2 Assay in the EU by Q1 2014.
Chembio's SURE CHECK(R) HIV 1/2 Assay For Rapid Point-of-Care Detection Of HIV Receives CE Mark Approval
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts